^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Vectibix (panitumumab)

    i
    Other names: ABX-EGF, E7.6.3, anti-EGFR monoclonal antibody , rHuMAb-EGFr
    Company:
    Amgen, Dr. Reddy’s, Takeda
    Drug class:
    EGFR inhibitor
    Related drugs:
    2d
    concept: The Safety and Efficacy of Cetuximab Beta Plus Fruquintinib With or Without Immune Checkpoint Inhibitorrs in First-line Treatment of RAS/BRAF Wild Type Unresectable Metastatic Colorectal Cancer (clinicaltrials.gov)
    P2, N=70, Recruiting, Zhejiang University
    New P2 trial • Checkpoint inhibition • IO biomarker
    |
    BRAF (B-raf proto-oncogene)
    |
    Erbitux (cetuximab) • Vectibix (panitumumab) • Tyvyt (sintilimab) • Fruzaqla (fruquintinib)
    5d
    Molecular Resonance Quantification and Label-Free Interactome Characterization of Total Proteome of Tumor Specimens Decipher Responder and Success Predictors in Colorectal Cancer Patients Treated With Panitumumab. (PubMed, Cancer Med)
    Combination of PIMS and NPOT coupled to label-free quantitative proteomics point towards the distinct panitumumab mode of action in CRC patients and highlights specific proteins as prognostic biomarkers which need further validation in a bigger cohort and multicentric investigation, ideally involving patient registry follow up data.
    Journal
    |
    CTNNB1 (Catenin (cadherin-associated protein), beta 1) • POLD1 (DNA Polymerase Delta 1) • PTPN1 (Protein Tyrosine Phosphatase Non-Receptor Type 1) • ENO1 (Enolase 1) • YBX1 (Y-Box Binding Protein 1) • CTNND1 (Catenin Delta 1) • ITGB2 (Integrin Subunit Beta 2) • LRIG1 (Leucine Rich Repeats And Immunoglobulin Like Domains 1) • NT5C (5', 3'-Nucleotidase, Cytosolic) • PRKDC (Protein Kinase, DNA-Activated, Catalytic Subunit) • HSP90AA1 (Heat Shock Protein 90 Alpha Family Class A Member 1Heat Shock Protein 90 Alpha Family Class A Member 1) • HSP90AB1 (Heat Shock Protein 90 Alpha Family Class B Member 1) • HSPA4 (Heat Shock Protein Family A (Hsp70) Member 4) • ITGB1 (Integrin Subunit Beta 1) • PPM1G (Protein Phosphatase, Mg2+/Mn2+ Dependent 1G) • YWHAZ (Tyrosine 3-Monooxygenase/Tryptophan 5-Monooxygenase Activation Protein Zeta) • HSPA8 (Heat Shock Protein Family A (Hsp70) Member 8) • NCAPD2 (Non-SMC Condensin I Complex Subunit D2)
    |
    Vectibix (panitumumab)
    8d
    Early-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients With mCRC (clinicaltrials.gov)
    P2, N=34, Active, not recruiting, University of Wisconsin, Madison | Recruiting --> Active, not recruiting | N=71 --> 34 | Trial completion date: Oct 2033 --> Oct 2029 | Trial primary completion date: Oct 2033 --> Oct 2029
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog) • MSI (Microsatellite instability)
    |
    BRAF mutation • BRAF V600
    |
    Erbitux (cetuximab) • 5-fluorouracil • Vectibix (panitumumab) • irinotecan • leucovorin calcium
    8d
    Efficacy of Anti-VEGF and Anti-EGFRs in Microsatellite Instable (MSI-H) Metastatic Colorectal Cancer in a Turkish Oncology Group (TOG) Cohort Study. (PubMed, Curr Oncol)
    dMMR/MSI-H mCRC is an entity with different tumor biology. We consider that dMMR/MSI-H mCRC patients with BRAF wild, MCS and subsequent IO have better outcomes with 1st line 5FU-based treatment with anti-VEGF/anti-EGFRs.
    Journal • MSi-H Biomarker • IO biomarker • MSI-H
    |
    BRAF (B-raf proto-oncogene) • MSI (Microsatellite instability)
    |
    MSI-H/dMMR • BRAF mutation • RAS mutation
    |
    Avastin (bevacizumab) • Erbitux (cetuximab) • 5-fluorouracil • Vectibix (panitumumab)
    9d
    Breakthroughs in KRAS G12C-mutant advanced colorectal cancer: from mechanisms to clinical practice (PubMed, Zhonghua Wei Chang Wai Ke Za Zhi)
    Recent phase I/II trials of KRAS G12C inhibitors have shown promising results, and the phase III CodeBreaK 300 study confirmed that sotorasib combined with panitumumab significantly improved efficacy compared with standard treatment, establishing a new therapeutic option for KRAS G12C-mutant metastatic CRC. Strategies under investigation include targeting alternative signaling pathways, developing next-generation inhibitors and specific degraders, and exploring multi-mechanism or multi-target combination strategies. This review systematically outlines the development of KRAS G12C inhibitors in mCRC, summarizes resistance mechanisms, and discusses emerging combination regimens, aiming to provide a theoretical basis and future directions for treatment optimization.
    Review • Journal
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    Vectibix (panitumumab) • Lumakras (sotorasib)
    10d
    Short- and Long-Term Outcomes of Neoadjuvant Chemotherapy in Operable Locally Advanced Colon Cancer: A Systematic Review. (PubMed, Cureus)
    The addition of targeted therapy based on biomarker status (e.g., panitumumab in KRAS-wildtype tumors) demonstrated significant improvements in DFS and OS...Its efficacy is highly dependent on careful patient selection based on disease stage and molecular characteristics. Future research should focus on randomized trials in high-risk populations and the integration of personalized treatment approaches.
    Review • Journal
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS wild-type • RAS wild-type
    |
    5-fluorouracil • Vectibix (panitumumab) • leucovorin calcium
    15d
    EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer (clinicaltrials.gov)
    P1, N=2, Active, not recruiting, Roswell Park Cancer Institute | Trial primary completion date: Dec 2025 --> Jul 2025
    Trial primary completion date
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • RAS (Rat Sarcoma Virus)
    |
    BRAF V600 • KRAS wild-type • BRAF wild-type • RAS wild-type • NRAS wild-type
    |
    Avastin (bevacizumab) • Erbitux (cetuximab) • 5-fluorouracil • Vectibix (panitumumab) • oxaliplatin • irinotecan • leucovorin calcium • CimaVax EGF (EGF-PTI)
    1m
    BDTX-4933-101: Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies (clinicaltrials.gov)
    P1/2, N=554, Recruiting, Institut de Recherches Internationales Servier | Phase classification: P1 --> P1/2 | N=100 --> 554 | Trial completion date: Dec 2026 --> Jun 2028 | Trial primary completion date: Jun 2026 --> Jun 2028
    Phase classification • Enrollment change • Trial completion date • Trial primary completion date
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog)
    |
    KRAS mutation • KRAS G12C • BRAF mutation • NRAS mutation • KRAS G12D • KRAS G12
    |
    Erbitux (cetuximab) • gemcitabine • 5-fluorouracil • Vectibix (panitumumab) • albumin-bound paclitaxel • oxaliplatin • irinotecan • leucovorin calcium • BDTX-4933
    1m
    EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer (clinicaltrials.gov)
    P1, N=2, Active, not recruiting, Roswell Park Cancer Institute | Suspended --> Active, not recruiting | N=42 --> 2
    Enrollment closed • Enrollment change
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • RAS (Rat Sarcoma Virus)
    |
    BRAF V600 • KRAS wild-type • BRAF wild-type • RAS wild-type • NRAS wild-type
    |
    Avastin (bevacizumab) • Erbitux (cetuximab) • 5-fluorouracil • Vectibix (panitumumab) • oxaliplatin • irinotecan • leucovorin calcium • CimaVax EGF (EGF-PTI)
    1m
    Comparative effectiveness of bevacizumab, cetuximab, and panitumumab for improving outcomes in metastatic colorectal cancer: a propensity overlap weighting analysis. (PubMed, Ann Coloproctol)
    Cetuximab and panitumumab were more effective than bevacizumab at improving survival outcomes and facilitating conversion surgery in left-sided mCRC. These findings highlight the importance of tumor laterality and molecular profiling in guiding therapeutic strategies.
    Journal • HEOR
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS wild-type • RAS wild-type
    |
    Avastin (bevacizumab) • Erbitux (cetuximab) • Vectibix (panitumumab)
    1m
    Postmarketing safety signals of cetuximab and panitumumab in the FAERS database: Real-World insights focus on population heterogeneity. (PubMed, Eur J Pharmacol)
    Cetuximab and panitumumab exhibit divergent, demography-modulated safety narratives. Cetuximab amplifies acute radio-toxicity whereas panitumumab elicits a quantitatively stronger, more persistent mucocutaneous and electrolyte injury that is magnified by female sex, advancing age, and non-medical reporters reporting. These population-specific pharmacovigilance signatures refine risk-benefit assessments and should inform individualized monitoring strategies in precision oncology.
    P4 data • Journal • Real-world evidence
    |
    EGFR (Epidermal growth factor receptor)
    |
    Erbitux (cetuximab) • Vectibix (panitumumab)
    1m
    CodeBreak101: Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101) (clinicaltrials.gov)
    P1, N=610, Active, not recruiting, Amgen | Recruiting --> Active, not recruiting | N=1200 --> 610 | Trial primary completion date: Jun 2026 --> Dec 2026
    Enrollment closed • Enrollment change • Trial primary completion date
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    Keytruda (pembrolizumab) • Mekinist (trametinib) • Tecentriq (atezolizumab) • Gilotrif (afatinib) • Ibrance (palbociclib) • carboplatin • paclitaxel • docetaxel • everolimus • Vectibix (panitumumab) • Lumakras (sotorasib) • pemetrexed • oxaliplatin • irinotecan • batoprotafib (TNO155) • vociprotafib (RMC-4630) • BI 1701963 • zeluvalimab (AMG 404)